Mapping US FDA's Biosimilar Pathway With Pink Sheet Drug Review Profiles
Executive Summary
First four 351(k) BLA approvals highlight emerging FDA positions on issues from naming to the role of biosimilar-specific data, as detailed in Pink Sheet's Drug Review Profile series.